Heron Therapeutics (HRTX) Total Non-Current Liabilities (2022 - 2026)

Heron Therapeutics has reported Total Non-Current Liabilities for 5 years, with the latest figure at $232.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 11.91% year-over-year to $232.2 million; the trailing twelve-month figure through Mar 2026 stood at $232.2 million (down 11.91% YoY), and the FY2025 full-year result was $236.7 million, down 11.06% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $232.2 million, down from $236.7 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $266.2 million in Q4 2024, with the low at $229.4 million in Q3 2025.
• Historically, Total Non-Current Liabilities has averaged $249.5 million across 5 years, with a median of $251.4 million in 2024.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities increased 8.34% — and 2025, when it fell 11.96%.
• Heron Therapeutics' Total Non-Current Liabilities stood at $237.1 million in 2022, then rose by 8.05% to $256.2 million in 2023, then advanced by 3.88% to $266.2 million in 2024, then retreated by 11.06% to $236.7 million in 2025, then decreased by 1.94% to $232.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $232.2 million (Q1 2026), $236.7 million (Q4 2025), and $229.4 million (Q3 2025), per Business Quant data.